DANIEL WILLIS: Open Payments
NPI 1699946376 · TEMPLETON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$523 in 27 payments from 12 companies in 2025. Trend: 2023 $15 · 2024 $271 · 2025 $523
Food & beverage: $523
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 6 | $170 |
| GlaxoSmithKline, LLC. | 5 | $85 |
| Novo Nordisk Inc | 3 | $48 |
| Lilly USA, LLC | 2 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Exact Sciences Corporation | 1 | $22 |
| PFIZER INC. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 3 | $19 |
Products named: DUPIXENT, TRELEGY ELLIPTA, SHINGRIX, Ozempic, JARDIANCE, REXULTI, GEMTESA, The Cologuard Plus Collection Kit.
Industry payments across CA — which companies pay providers there.
